Dennis Langer bought $129k of QNRX
director at Quoin Pharmaceuticals, Ltd.. 15,152 shares at an average of $8.49, traded Oct 14, 2025, filed Oct 15, 2025.
Score components
- +15RoleDirector
- +11Trade size$129k at market
- +10Relative to holdingsHoldings up 1515200%
- +8Price context54% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.6%, 3m -26.2%, 6m -57.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-099782, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2025 | POpen-market purchase ADSs | +15,152 | $8.49 | $129k | 15,153 | Oct 15, 2025 |
| Oct 14, 2025 | POpen-market purchase Series H Warrants (Right to Buy)derivative | +15,152 | - | - | 15,152 | Oct 15, 2025 |
| Oct 14, 2025 | POpen-market purchase Series I Warrants (Right to Buy)derivative | +15,152 | - | - | 15,152 | Oct 15, 2025 |
| Oct 14, 2025 | POpen-market purchase Series J Warrants (Right to Buy)derivative | +15,152 | - | - | 15,152 | Oct 15, 2025 |
| Oct 14, 2025 | POpen-market purchase Series K Warrants (Right to Buy)derivative | +15,152 | - | - | 15,152 | Oct 15, 2025 |
Related signals
Other insiders at Quoin Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $100k 20,490 shares | +119% | |
| 38Weak | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $30k 6,146 shares | +18% | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Sally Bridget Lawlor Chief Financial Officer | $50k 10,244 shares | +2328% | |
| 60Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $100k 20,490 shares | +119% | |
| 58Moderate | Quoin Pharmaceuticals, Ltd. | Denise P. Carter Chief Operating Officer | $250k 555,556 shares | +1180% | |
| 46Moderate | Quoin Pharmaceuticals, Ltd. | Anthony James Culverwell director | $45k 100,000 shares | first purchase | |
| 54Moderate | Quoin Pharmaceuticals, Ltd. | Gordon Dunn Chief Financial Officer | $55k 122,221 shares | +424% | |
| 63Notable | Quoin Pharmaceuticals, Ltd. | Michael Myers Chief Executive Officer | $250k 555,556 shares | +1176% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.